Venkatesh Lakshminarayanan, MD
Pulmonary Disease · Atlanta, GANPI 1568580744
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Pinnacle Biologics, Inc accounts for 71.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2021 at $9,934 and has fallen 59.9% since, to $3,982 in 2025. Among pulmonary disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $155.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pinnacle Biologics, Inc$23K
- Intuitive Surgical$5K
- Johnson & Johnson$1K
- AstraZeneca$906
- Veran Medical Technologies, Inc.$713
- GSK$442
- plus $2K from 25 others
Across 2 payments — averaging $340.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Concordia Laboratories Inc.$680
What the payments were for
- Consulting fees$3,85012%
- Speaking & faculty fees$16,54551%
- Travel & lodging$3,94212%
- Food & beverage$5,71818%
- Education$2,5238%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pinnacle Biologics, Inc | 44 | $23,149 |
| Intuitive Surgical | 27 | $4,724 |
| Johnson & Johnson | 23 | $1,012 |
| AstraZeneca | 25 | $906 |
| Veran Medical Technologies, Inc. | 7 | $713 |
| GSK | 27 | $442 |
| Olympus America Inc. | 5 | $338 |
| Insmed, Inc. | 5 | $154 |
| Regeneron Healthcare Solutions, Inc. | 4 | $122 |
| Medical Device Business Services, Inc. | 1 | $121 |
| Actelion Pharmaceuticals US, Inc. | 4 | $119 |
| Amgen | 5 | $107 |
| Verona Pharma, Inc. | 3 | $81 |
| Philips North America LLC | 4 | $76 |
| Boehringer Ingelheim | 3 | $62 |
| Merck | 2 | $53 |
| AbbVie | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Novartis | 2 | $44 |
| Sanofi | 1 | $37 |
| Mylan Specialty L.p. | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Grifols USA, LLC | 1 | $26 |
| United Therapeutics Corporation | 1 | $26 |
| Pfizer | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Chiesi USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Inogen, Inc. | 1 | $15 |
| Inari Medical, Inc. | 1 | $14 |
| Ambu Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Photofrin$22,290
- Da Vinci Surgical System$3,938
- Spin$600
- Monarch Platform$474
- FASENRA$459
- Spiration Valve System$147
How this compares
$32,578 in reported general payments places this provider in the 90th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 16 | $207,501 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 145 | $101,694 |
| Spiriva RespimatTiotropium Bromide | 46 | $25,788 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $17,346 |
| XareltoRivaroxaban | 19 | $15,281 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $11,880 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,376 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $5,411 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $4,611 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $2,175 |
| Mycophenolate Mofetil | 12 | $1,423 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $899 |
| Ventolin HfaAlbuterol Sulfate | 14 | $783 |
| Azelastine Hcl | 11 | $188 |
| Ipratropium Bromide | 12 | $169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $62 | $233,28962 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $442 | $125,417200 claims |
| Johnson & JohnsonXarelto | $1,012 | $15,28119 claims |
| AstraZenecaSymbicort | $906 | $11,88044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Atlanta
- Colin SwensonAtlanta$255K
- Eric FlenaughAtlanta$93K
- Gregory MartinAtlanta$88K
- Victor TsengAtlanta$55K
- Ralitza MartinAtlanta$48K
- Sisir AkkineniAtlanta$21K
- Gerald StatonAtlanta$21K
- Mirza AliAtlanta$16K
- Srihari VeeraraghavanAtlanta$16K
- Lawrence McDermottSavannah$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.